Press Releases

12/03/09

QUIGLEY CEO, TED KARKUS, ANNOUNCES PHASE ONE OF 2010 STRATEGIC PLAN

07/22/09

QUIGLEY CORPORATION ANNOUNCES FINAL RESULTS OF QUIGLEY PHARMA'S PHASE IIB STUDY

07/17/09

TED KARKUS NAMED CEO OF THE QUIGLEY CORPORATION

07/10/09

DR. RICHARD ROSENBLOOM RESUMES SERVICES TO THE QUIGLEY CORPORATION’S PHARMA SUBSIDIARY

06/18/09

TED KARKUS APPOINTED INTERIM CHIEF EXECUTIVE OFFICER OF THE QUIGLEY CORPORATION

06/17/09

COLD-EEZE® LOZENGES NOT AFFECTED BY FDA ADVISORY FOR ZICAM® INTRA-NASAL PRODUCTS

06/15/09

Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation

06/12/09

Guy J. Quigley Resigns as Chairman and CEO

05/18/09

The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure

04/30/09

Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy

11/12/08

Quigley Announces Completion of Phase IIb Clinical Study Of QR-333 For Diabetic Peripheral Neuropathy On November 25, 2008

09/16/08

Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens

09/16/08

Quigley Announces Positive Follow Up Study of Poultry with Infectious Bronchitis

05/14/08

Quigley Announces Successful Poultry Study of Chickens with Infectious Bronchitis

09/11/07

Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy

08/01/07

Quigley Evaluates Regulatory and Market Opportunities for Anti-Inflammatory / Cytokine Modifying Compound

07/30/07

Quigley Begins Human Trial to Investigate Effects of Broad Spectrum Anti-Inflammatory Compound on Metabolic Syndrome Patients

06/20/07

Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases -- Human Study to Follow --

02/20/07

The Quigley Corporation and the Israeli Ministry of Agriculture (MOAG) Will Collaborate to Test Quigley Pharma QR-441(a) Broad Spectrum Anti-Viral Against Avian Flu H5N1 in Chickens

02/12/07

Quigley Granted Patent for Prophylactic and Anti-Transmissivity Uses of an Anti-Microbial Composition

01/22/07

Quigley QR-443 Cachexia Compound Demonstrates Dose Response Effectiveness in Second Preliminary Animal Model Study

01/08/07

Quigley’s Broad Spectrum Anti-Viral QR-441(a) Shown to be Effective Against Two Problematic Pathogens to the Poultry Industry

12/28/06

Quigley Announces Results of In-Vitro Studies for the Potential Treatment of Herpes Keratitis and Next Steps for Its QR-435 Compound

12/06/06

The Quigley Corporation to Present at the NYSSA Biotech/Specialty Pharma Conference

11/20/06

Quigley Pharma’s QR-333 Phase IIb Clinical Study Has Commenced

10/03/06

Quigley’s Radioprotective Compound QR-336 Shown to be Most Effective in Oral and Subcutaneous Injection Dose Forms in Animal Model Study

09/26/06

Following Positive Data Showing QR-333 to be Safe, Quigley Pharma to Proceed with Phase IIB Clinical Trials for Its Lead Investigational Compound Formulated for Diabetic Neuropathy

08/28/06

Quigley Launches Redesigned Quigley Pharma Web Site

08/21/06

Quigley Assigned Second Patent Covering Peripheral Neural and Vascular Ailments

08/08/06

Quigley Pharma Compound QR-443 Effective

07/12/06

Quigley Pharma Announces Continued Progress in Natural Broad Spectrum Anti-Viral for Use in Preventing Spread of Avian Flu in Poultry Stocks

05/22/06

Quigley to Conduct Further Testing of QR-435 for Ocular Herpes in Animals

05/10/06

Quigley to Commence Medical Feed Poultry Study for Its QR-441(a) Investigational New Animal Drug Designed to Combat Avian Flu

05/08/06

Quigley Pharma Scheduled to Commence Clinical Testing of QR-333, Its Topical Diabetic Peripheral Neuropathy Investigational New Drug

04/10/06

Quigley to Commence Human Testing of its QR-333 Topical Diabetic Peripheral Neuropathy Investigational New Drug

04/03/06

Quigley Enlists Leading Radiation Oncology Researcher to Assist in the Development Plan and Radiological Testing of QR-336 Compound

03/21/06

Quigley Initiates Development Plan to Test QR-441(a) against Avian Flu in Poultry Stocks

03/07/06

Quigley Submits Investigational New Drug Application to the FDA for its QR-333 Diabetic Peripheral Neuropathy Compound

02/13/06

Quigley Pharma Anti-Viral Compound QR-435 Demonstrates Potent Antiviral Activity Against Ocular and Genital Herpes

01/31/06

FDA Issues Investigational New Animal Drug (INAD) number to Quigley Pharma to Study Its Anti-Inflammatory Compound QR-440 on Arthritis in Dogs

01/23/06

Quigley Pharma's Scientific Advisory Board is Encouraged by Research Results; Strongly Supports Next Stage of Development

01/18/06

Quigley Pharma's Dr. Richard Rosenbloom to Present Results of Bird Flu Compound Research at Retroscreen Virology Conference